Novo Nordisk A/S (NVO)

42.81 +0.62 (+1.47%) USD  |  NYSE  |  Jun 10, 16:00
43.39 +0.58 (+1.35%) Pre-Market: 07:37
More

Novo Nordisk SG&A Expense (Quarterly) : 2.070B for March 31, 2026

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for NVO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
March 31, 2026 2.070B
December 31, 2025 2.718B
September 30, 2025 2.799B
June 30, 2025 2.865B
March 31, 2025 2.273B
December 31, 2024 2.900B
September 30, 2024 2.443B
June 30, 2024 2.322B
March 31, 2024 2.098B
December 31, 2023 2.686B
September 30, 2023 2.054B
June 30, 2023 2.252B
March 31, 2023 1.944B
December 31, 2022 2.069B
September 30, 2022 1.706B
June 30, 2022 1.693B
March 31, 2022 1.682B
December 31, 2021 1.970B
September 30, 2021 1.608B
June 30, 2021 1.444B
March 31, 2021 1.488B
December 31, 2020 1.756B
September 30, 2020 1.441B
June 30, 2020 1.215B
March 31, 2020 1.256B
Date Value
December 31, 2019 1.596B
September 30, 2019 1.307B
June 30, 2019 1.269B
March 31, 2019 1.195B
December 31, 2018 1.529B
September 30, 2018 1.257B
June 30, 2018 1.270B
March 31, 2018 1.207B
December 31, 2017 1.489B
September 30, 2017 1.168B
June 30, 2017 1.128B
March 31, 2017 1.104B
December 31, 2016 1.315B
September 30, 2016 1.181B
June 30, 2016 1.175B
March 31, 2016 1.130B
December 31, 2015 1.350B
September 30, 2015 1.177B
June 30, 2015 1.195B
March 31, 2015 1.056B
December 31, 2014 1.300B
September 30, 2014 1.203B
June 30, 2014 1.168B
March 31, 2014 1.082B
December 31, 2013 1.379B

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 140.76M
GSK Plc 2.855B
Johnson & Johnson 6.034B
Eli Lilly & Co. 2.934B
Merck & Co., Inc. 2.70B